GlassScriptPhysician profile
Roxanne A Lamarre
NPI 1881124642
$1,527.82
in general payments reported to CMS, 2019-2025
25 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $372 · 2022: $429 · 2023: $149 · 2024: $333 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $223.69 | 2021-2022 | |
| Exeltis, USA INC. | $174.43 | 2021-2025 | Slynd |
| Hologic Sales and Service, LLC | $159.37 | 2023-2025 | Novasure, Omni Hysteroscope, Acessa Provu System |
| Abbvie INC. | $156.95 | 2022-2024 | |
| Amgen INC. | $132.45 | 2022 | |
| Pfizer INC. | $119.64 | 2023-2025 | |
| Astellas Pharma US INC | $78.43 | 2024-2025 | Veozah |
| Shield Therapeutics INC | $63.83 | 2023-2024 | Accrufer |
| Mayne Pharma Commercial LLC | $51.09 | 2025 | |
| Intuitive Surgical, INC. | $49.97 | 2021 | |
| Organon LLC | $37.79 | 2023-2024 | Nexplanon |
| Sumitomo Pharma America, INC. | $31.07 | 2023-2024 | Myfembree |
| Evofem Biosciences, INC. | $30.42 | 2021 | |
| Baxter Healthcare | $23.45 | 2022 | |
| Trevena, INC. | $22.86 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $21.47 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.74 | 2025 | |
| Axonics, INC. | $19.52 | 2023 | Axonics |
| Scynexis, INC. | $19.14 | 2022 | |
| Solventum Corporation | $18.36 | 2025 | Prevena |
| Glaxosmithkline, LLC. | $18.36 | 2021 | |
| Ethicon US, LLC | $15.17 | 2025 | Stratafix, Vistaseal, Dermabond Prineo |
| Myovant Sciences INC. | $14.52 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.26 | 2024 | Xifaxan |
| Avion Pharmaceuticals | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxanne Lamarre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.